glp-1 drug market competition 2025 Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 GLP-1 Receptor Agonist Market Size
Description
Clinical Significance If approved, orforglipron would be the first oral medication specifically approved for chronic weight management that activates the GLP-1 receptor without requiring injection, absorption enhancers, or dietary restrictions
Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Korn O, Maluenda F, Diaz JC, Rencoret G, Braghetto I, Castillo J, Poniachik J, Videla LA
The first is the obesity epidemic
Clin Obstet Gynecol
Gallwitz B (2012) Anorexigenic effects of GLP-1 and its analogues
10.1038/npp.2015.47 24 HayesM
